CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 8.36 HKD -0.71% Market Closed
Market Cap: 4.8B HKD
Have any thoughts about
CARsgen Therapeutics Holdings Ltd?
Write Note

CARsgen Therapeutics Holdings Ltd
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CARsgen Therapeutics Holdings Ltd
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Retained Earnings
-ÂĄ8B
CAGR 3-Years
-68%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Retained Earnings
-ÂĄ57.7B
CAGR 3-Years
-28%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Retained Earnings
-ÂĄ15B
CAGR 3-Years
-12%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Retained Earnings
ÂĄ8.2B
CAGR 3-Years
70%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Retained Earnings
ÂĄ29.1B
CAGR 3-Years
28%
CAGR 5-Years
54%
CAGR 10-Years
47%
Imeik Technology Development Co Ltd
SZSE:300896
Retained Earnings
ÂĄ3.1B
CAGR 3-Years
56%
CAGR 5-Years
84%
CAGR 10-Years
N/A
No Stocks Found

CARsgen Therapeutics Holdings Ltd
Glance View

Market Cap
4.8B HKD
Industry
Biotechnology

CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

Intrinsic Value
12.81 HKD
Undervaluation 35%
Intrinsic Value
Price

See Also

What is CARsgen Therapeutics Holdings Ltd's Retained Earnings?
Retained Earnings
-8B CNY

Based on the financial report for Dec 31, 2023, CARsgen Therapeutics Holdings Ltd's Retained Earnings amounts to -8B CNY.

What is CARsgen Therapeutics Holdings Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 3Y
-68%

Over the last year, the Retained Earnings growth was -10%. The average annual Retained Earnings growth rates for CARsgen Therapeutics Holdings Ltd have been -68% over the past three years .

Back to Top